ADVISORY, Sept. 05, 2017 --
What:
Sarepta Therapeutics, Inc. (Nasdaq:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, will visit the Nasdaq MarketSite in Times Square.
In recognition of World Duchenne Awareness Day, Douglas Ingram, Sarepta’s President & CEO, will ring the Closing Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Wednesday, September 6, 2017 – 3:45 p.m. to 4:00 p.m. ET
Sarepta Therapeutics Contact:
Ian Estepan
(617) 274-4052
[email protected]
Nasdaq MarketSite Media Contact:
Emily Pan
(646) 441-5120
[email protected]
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/
Webcast:
A live stream of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com
-NDAQA-


Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Apple Turns 50: From Garage Startup to AI Crossroads
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 



